With all weight-related factors in the model, only waist circumference was related to LBP in women. For women, the odds ratios of LBP
were 1.2 (95% confidence interval: 0.8, 1.8) for a waist circumference of 80-87.9 cm and 1.8 ( 95% confidence interval: 1.0, 3.2) for a waist circumference of >= 88 cm compared with a waist circumference of < 80 cm. This association was independent of C- reactive protein, leptin, and adiponectin levels. The authors’ findings in a relatively young population suggest that abdominal obesity may increase the risk of VX-661 in vitro LBP in women.”
“The enzyme catalase catalyzes the breakdown of hydrogen peroxide AZD1480 into oxygen and water. It is the main regulator of hydrogen peroxide metabolism. Hydrogen
peroxide is a highly reactive small molecule formed as a natural byproducts of energy metabolism. Excessive concentrations may cause significant damages to protein, DNA, RNA and lipids. Low levels in muscle cells, facilitate insulin signaling. Acatalasemia is a result of the homozygous mutations in the catalase gene, has a worldwide distribution with 12 known mutations. Increased hydrogen peroxide, due to catalase deficiency, plays a role in the pathogenesis of several diseases such as diabetes mellitus. Diabetes mellitus is a disorder caused by multiple genetic and environmental factors. Examination of Hungarian diabetic and acatalasemic patients showed that an increased frequency
of catalase gene mutations exists among diabetes patients. Inherited catalase deficiency may increase the risk of type 2 diabetes mellitus, especially for females. Early onset of type 2 diabetes occurs with inherited catalase deficiency. Low levels of SOD and glutathione peroxidase could contribute to complications caused NVP-HSP990 by increased oxidative stress. (c) 2012 Elsevier Inc. All rights reserved.”
“This minireview highlights the importance of cannabidiol (CBD) as a promising drug for the therapy of inflammatory bowel diseases (IBD). Actual pharmacological treatments for IBD should be enlarged toward the search for low-toxicityand low-cost drugs that may be given alone or in combination with the conventional anti-IBD drugs to increase their efficacy in the therapy of relapsing forms of colitis. In the past, Cannabis preparations have been considered new promising pharmacological tools in view of their anti-inflammatory role in IBD as well as other gut disturbances. However, their use in the clinical therapy has been strongly limited by their psychotropic effects. CBD is a very promising compound since it shares the typical cannabinoid beneficial effects on gut lacking any psychotropic effects.